- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05872659
Mesenchymal Stem Cells for Immune Non-responder Patients With HIV Infection
A Clinical Study to Evaluate the Safety and Efficacy of Human Umbilical Cord Mesenchymal Stem Cells Combined With Antiviral Therapy in the Treatment of AIDS Patients With Immune Non-responder
The goal of this clinical trial is to explore the effect of mesenchymal stem cell therapy on immune non-responder patients. The main questions it aims to answer are:
- Efficacy of human umbilical cord mesenchymal stem cells combined with antiviral therapy in the treatment of AIDS patients with immune non-response.
- Safety of human umbilical cord mesenchymal stem cells combined with antiviral therapy in AIDS patients with immune non-response.
Participants will receive CD4,CD4/CD8, and RNA viral load tests and will be randomly assigned to either saline or mesenchymal stem cell therapy.
Investigators will evaluate the safety and efficacy of mesenchymal stem cell therapy based on examination results.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Highly active antiretroviral therapy (HAART) is an effective means to inhibit virus replication, increase the number of CD4+T lymphocytes and reduce mortality in HIV-infected people. However, it has been found that around 10% - 40% of patients have not achieved ideal immune function reconstruction under the condition of good viral load control and are referred to as"inadequate immunological responders" or "immune non-responders" (INRs).
A series of intervention measures have been proposed for patients with immune non-response, including growth hormone therapy, immunosuppressive therapy, cytokine therapy, traditional Chinese medicine therapy, etc., but there is no specific and effective treatment in clinical practice.
Mesenchymal stem cells (MSCs) are pluripotent stem cells with high self-renewal ability and multi-directional differentiation potential derived from mesoderm. MSCs have considerable therapeutic effects due to their migration, differentiation, immune-modulation, and regeneration abilities. The immunomodulatory effect of mesenchymal stem cells can inhibit the excessive immune activation in patients. At the same time, the paracrine effect of mesenchymal stem cells can also regulate the disordered microenvironment and promote the repair of damaged cells and tissues.
This is a randomised, placebo-controlled, clinical trial to evaluate the safety and feasibility of a 3-doses treatment regimen with MSCs (1 million cells/Kg MSCs, months 0-1-2) in HIV infected adults with immune non-response. Subjects are block randomised (1:1) to receive either MSCs (n=10), or placebo (n=10), as the control treatment. Changes in CD4+Tcount and CD4/8,adverse events, opportunistic infection signs are evaluated as determinants of safety and efficacy of MSCs. Study endpoints are measured along a follow-up period of 12 months, that includes 7 visits.
Study Type
Enrollment (Anticipated)
Phase
- Early Phase 1
Contacts and Locations
Study Contact
- Name: Chenfan Liu
- Phone Number: 17862958810
- Email: 1780966676@qq.com
Study Locations
-
-
Shandong
-
Jinan, Shandong, China
- Recruiting
- Shandong Public Health Clinical Center
-
Contact:
- Chenfan Liu
- Phone Number: 17862958810
- Email: 1780966676@qq.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Confirmed HIV infection.
- ≥18 years old, gender unlimited.
- ≥12 months of continuous antiviral therapy and at least 2 viral loads (3 months or more apart) < 50 Copies/mL at screening.
- The antiviral regimen was not changed in the 12 months prior to enrollment.
- CD4+T lymphocyte count < 200 μL-1 in patients receiving antiviral therapy for more than 1 year and less than 2 years or < 350 μL-1 in patients receiving antiviral therapy for ≥ 2 years.
- Understand and sign the informed consent.
Exclusion Criteria:
- Infection with other viruses: HBV-DNA positive, HCV RNA positive, anti-Hav IgM, anti-HDV IgM and anti-HEV IgM positive and ALT >80 IU/L, anti-TP positive.
- Active and uncontrollable infection.
- Malignant tumor or tumor history.
- Complicated with abnormal function of heart, liver, lung, kidney and other major organs.
- When the laboratory test satisfies any item (WBC < 3.5*10^9/L; PLT < 80*10^9/L; HGB < 100 g/L).
- Drug dependent.
- Pregnant and lactating women.
- Severe allergic constitution, or known allergy to the study drug and its components;
- Accepting immunosuppressants or other immunomodulators (including thymosin) or systemic cytotoxic agents within 6 months prior to screening.
- Participated in other clinical studies within 3 months prior to this study.
- patients with any condition which the investigator or treating physician feels would interfere with the trial or the safety of the subject.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Control group
Participants will receive continuous antiviral therapy and saline placebo (iv, 100 mL) treatment on Day 0,Day30,Day60 and followed up for 48 weeks.
|
iv at D0, D30, D60
|
Experimental: Treatment group
Participants will receive continuous antiviral therapy and Mesenchymal stem cells (1*10^6/kg subject weight, iv, 100 mL) treatment on Day 0,Day30,Day60 and followed up for 48 weeks.
|
iv at D0, D30, D60
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in CD4+T cell counts
Time Frame: Change from Baseline at 12 months
|
the total CD4+T cell counts compared with CD4 T cell counts at baseline
|
Change from Baseline at 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
change in CD4/CD8
Time Frame: Change from Baseline at 12 months
|
the value of CD4/CD8 compared with CD4/CD8 value at baseline
|
Change from Baseline at 12 months
|
change in RNA viral load
Time Frame: Change from Baseline at 12 months
|
the RNA viral load compared with RNA viral load at baseline
|
Change from Baseline at 12 months
|
The incidence of opportunistic infections
Time Frame: 12 months
|
Incidence of opportunistic infections throughout the study period
|
12 months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Chenfan liu, Shandong Public Health Clinical Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- Slow Virus Diseases
- Urogenital Diseases
- Genital Diseases
- HIV Infections
- Acquired Immunodeficiency Syndrome
Other Study ID Numbers
- MSCT-A-22
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on AIDS Virus
-
National Center for AIDS/STD Control and Prevention...Completed
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingHIV Infection | AIDS-Related Diffuse Large B-cell Lymphoma | AIDS-Related Primary Effusion Lymphoma | AIDS-Related Burkitt Lymphoma | AIDS-Related Plasmablastic Lymphoma | AIDS Related Non-Hodgkin LymphomaUnited States
-
University of LouisvilleCompleted
-
Columbia UniversityNational Institute on Drug Abuse (NIDA)CompletedHIV/AIDS and InfectionsKazakhstan
-
Johns Hopkins UniversityUniversity of South Florida; Universidad San Francisco de QuitoCompleted
-
New York UniversityNYU Langone HealthUnknownHIV-infection/AIDSUnited States
-
Tobira Therapeutics, Inc.ViiV HealthcareCompletedHIV-infection/AIDSUnited States
-
Gaia Medical InstituteAIDS Healthcare FoundationCompleted
-
University of TartuNational Institute for Health Development, EstoniaCompletedHIV | Medication Adherence | AIDSEstonia
-
National Center for Women and Children's Health...National Center for AIDS/STD Control and Prevention, China CDC; Guangdong Provincial... and other collaboratorsCompleted
Clinical Trials on normal saline
-
Texas Cardiac Arrhythmia Research FoundationSuspendedVentricular ArrythmiaUnited States
-
The Catholic University of KoreaCompleted
-
Texas Cardiac Arrhythmia Research FoundationCompleted
-
Ann & Robert H Lurie Children's Hospital of ChicagoWithdrawn
-
MemorialCare Health SystemCompletedLength of Labor | Second Stage of Labor | Intravenous Hydration of LaborUnited States
-
University of HaifaWestern Galilee Hospital-NahariyaRecruiting
-
McMaster UniversityGlaxoSmithKline; University of ManchesterRecruitingAsthma | Eosinophilic Bronchitis | Chronic CoughCanada
-
University of MichiganRadiological Society of North AmericaTerminated
-
Virginia Commonwealth UniversityUnited States Department of DefenseWithdrawn
-
Qassim UniversityCompletedApical Periodontitis | Post Operative Pain | Dental Pulp NecrosesSaudi Arabia